Is increased antidepressant exposure a contributory factor to the obesity pandemic?

Translational Psychiatry

Volumn 6, Issue 3, 2016, Pages

  Lee, S H ^a   Paz Filho, G ^a   Mastronardi, C ^a   Licinio, J ^b   Wong, M L ^b  

^a Biology and Environment   (Australia)

^b FLINDERS UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; FLUOXETINE; MIRTAZAPINE; SEROTONIN UPTAKE INHIBITOR;

BODY WEIGHT; BODY WEIGHT GAIN; BODY WEIGHT LOSS; CHRONIC STRESS; DRUG EFFECT; DRUG EXPOSURE; DRUG MECHANISM; DSM-5; GENETIC BACKGROUND; GENETIC POLYMORPHISM; HUMAN; MAJOR DEPRESSION; NONHUMAN; OBESITY; PANDEMIC; REVIEW; DEPRESSIVE DISORDER, MAJOR; HYPOPHYSIS ADRENAL SYSTEM; HYPOTHALAMUS HYPOPHYSIS SYSTEM; MENTAL STRESS; METABOLISM; RISK FACTOR; WEIGHT GAIN;

ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; HUMANS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; OBESITY; PANDEMICS; PITUITARY-ADRENAL SYSTEM; RISK FACTORS; SEROTONIN UPTAKE INHIBITORS; STRESS, PSYCHOLOGICAL; WEIGHT GAIN;

EID: 84984564001     PISSN: None     EISSN: 21583188     Source Type: Journal    
DOI: 10.1038/tp.2016.25     Document Type: Review

References (135)

1. Kupfer DJ, Frank E, Phillips ML. Major depressive disorder: new clinical, neuro-biological, and treatment perspectives. Lancet 2012; 379: 1045–1055.
2. Association AM (2013). Policy H-440.842. Recognition of Obesity as a Disease.
3. World Health Organization (2012). In: Depression. Fact sheet No. 369.
4. Beevers CK. Introduction: Evidence-Based Practice for Major Depressive Disorder. In: Springer DW, Rubin A, Beevers CG (eds.), Treatment of depression in adolescents and adults.1st edn. John Wiley & Sons, Inc.: Hoboken, NJ, 2011.
5. Greenberg PE, Fournier AA, Sisitsky T, Pike CT, Kessler RC The economic burden of adultswith major depressive disorder in the United States (2005 and 2010). J Clin Psychiatry 2015; 76: 155–162.
6. National Survey of Mental Health and Wellbeing: Summary of Results Statistics. Australian Bureau of Statistics: Canberra, Australia, 2007.
7. Data and statistics, prevalence of mental disorders. In: Noncommunicable Dis-ease, Mental Health. World Health Organization: WHO regional office for Europe, 2014.
8. Finkelstein EA, Trogdon JG, Cohen JW, Dietz W. Annual medical spending attributable to obesity: payer-and service-specific estimates.Health Aff (Mill-wood) 2009; 28: w822–w831.
9. Flegal KM, Carroll MD, Kit BK, Ogden CL. Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999-2010. JAMA 2012; 307: 491–497.
10. Park J, Morley TS, Kim M, Clegg DJ, Scherer PE. Obesity and cancer--mechanisms underlying tumour progression and recurrence. Nat Rev Endocrinol 2014; 10: 455–465.
11. Drager LF, Togeiro SM, Polotsky VY, Lorenzi-Filho G. Obstructive sleep apnea: a cardiometabolic risk in obesity and the metabolic syndrome. J Am Coll Cardiol 2013; 62: 569–576.
12. Jagielski AC, Brown A, Hosseini-Araghi M, Thomas GN, Taheri S. The association between adiposity, mental well-being, and quality of life in extreme obesity. PLoS ONE 2014; 9: e92859.
13. Rosmond R, Lapidus L, Mårin P, Björntorp P. Mental distress, obesity and body fat distribution in middle-aged men. Obes Res 1996; 4: 245–252.
14. Markowitz S, Friedman MA, Arent SM. Understanding the relation between obesity and depression: causal mechanisms and implications for treatment. Clin Psychol 2008; 15: 1–20.
15. Becker E, Margraf J, Türke V, Soeder U, Neumer S. Obesity and mental illness in a representative sample of young women. Int J Obes Relat Metab Disord 2001; 25: S5.
16. Onyike CU, Crum RM, Lee HB, Lyketsos CG, Eaton WW. Is obesity associated with major depression? Results from the Third National Health and Nutrition Examination Survey. Am J Epidemiol 2003; 158: 1139–1147.
17. Roberts RE, Deleger S, Strawbridge WJ, Kaplan GA. Prospective association between obesity and depression: evidence from the Alameda County Study. Int J Obes 2003; 27: 514–521.
18. Richardson LP, Davis R, Poulton R, McCauley E, Moffitt TE, Caspi A et al. A longitudinal evaluation of adolescent depression and adult obesity. Archiv Pediatr Adolesc Med 2003; 157: 739–745.
19. Akbaraly TN, Kivimäki M, Brunner EJ, Chandola T, Marmot MG, Singh-Manoux A et al. Association between metabolic syndrome and depressive symptoms in middle-aged adults: results from the Whitehall II study. Diabetes Care 2009; 32: 499–504.
20. Kinder LS, Carnethon MR, Palaniappan LP, King AC, Fortmann SP. Depression and the metabolic syndrome in young adults: findings from the Third National Health and Nutrition Examination Survey. Psychosom Med 2004; 66: 316–322.
21. Gil K, Radziłłowicz P, Zdrojewski T, Pakalska-Korcala A, Chwojnicki K, Piwoński J et al. Relationship between the prevalence of depressive symptoms and metabolic syndrome. Results of the SOPKARD project. Kardiol Pol 2006; 64: 464.
22. Heiskanen TH, Niskanen LK, Hintikka JJ, Koivumaa-Honkanen HT, Honkalampi KM, Haatainen KM et al. Metabolic syndrome and depression: a cross-sectional analysis. J Clin Psychiatry 2006; 67: 1422.
23. Räikkönen K, Matthews KA, Kuller LH. Depressive symptoms and stressful life events predict metabolic syndrome among middle-aged women: a comparison of World Health Organization, adult treatment panel III, and international diabetes foundation definitions. Diabetes Care 2007; 30: 872–877.
24. Rikknen K, Matthews KA, Kuller LH. The relationship between psychological risk attributes and the metabolic syndrome in healthy women: antecedent or con-sequence?. Metabolism 2002; 51: 1573–1577.
25. Larura AP, Debra JB, Gu Q. 2011. Antidepressant Use in Persons Aged 12 and Over: United States, 2005–2008, NCHS Data Brief No. 76.
26. OECD Health at a Glance: Europe 2012. OECD Publishing: Paris, France, 2012.
27. Australian Health Survey: First Results, 2011-12. Mental Health Series Australian Institute of Health and Welfare: Canberra, Australia, 2012.
28. Diagnostic and Statistical Manual Mental Disorders-V. American Psychiatric Association: Washington, DC, 2013; vol. V.
29. Duman RS, Monteggia LM. A neurotrophic model for stress-related mood dis-orders. Biol Psychiatry 2006; 59: 1116–1127.
30. Wong M-L, Licinio J. From monoamines to genomic targets: a paradigm shift for drug discovery in depression. Nat Rev Drug Discov 2004; 3: 136–151.
31. Pariante CM, Lightman SL. The HPA axis in major depression: classical theories and new developments. Trends Neurosci 2008; 31: 464–468.
32. Vreeburg SA, Hoogendijk WG, van Pelt J, Derijk RH, Verhagen JC, van Dyck R et al. Major depressive disorder and hypothalamic-pituitary-adrenal axis activity: Results from a large cohort study. Arch Gen Psychiatry 2009; 66: 617–626.
33. Trejo JL, Llorens-Martín MV, Torres-Alemán I. The effects of exercise on spatial learning and anxiety-like behavior are mediated by an IGF-I-dependent mechanism related to hippocampal neurogenesis. Mol Cell Neurosci 2008; 37: 402–411.
34. Hoshaw BA, Malberg JE, Lucki I. Central administration of IGF-I and BDNF leads to long-lasting antidepressant-like effects. Brain Res 2005; 1037: 204–208.
35. Malberg JE, Platt B, Rizzo SJS, Ring RH, Lucki I, Schechter LE et al. Increasing the levels of insulin-like growth factor-I by an IGF binding protein inhibitor produces anxiolytic and antidepressant-like effects. Neuropsychopharmacology 2007; 32: 2360–2368.
36. Duman CH, Schlesinger L, Terwilliger R, Russell DS, Newton SS, Duman RS. Peripheral insulin-like growth factor-I produces antidepressant-like behavior and contributes to the effect of exercise. Behav Brain Res 2009; 198: 366–371.
37. Jow G-M, Yang T-T, Chen C-L. Leptin and cholesterol levels are low in major depressive disorder, but high in schizophrenia. J Affect Disord 2006; 90: 21–27.
38. Kraus T, Haack M, Schuld A, Hinze-Selch D, Pollmaecher T. Low leptin levels but normal body mass indices in patients with depression or schizophrenia. Neu-roendocrinology 2001; 73: 243–247.
39. Westling S, Ahrén B, Träskman-Bendz L, Westrin Å. Low CSF leptin in female suicide attempters with major depression. J Affect Disord 2004; 81: 41–48.
40. Atmaca M, Kuloglu M, Tezcan E, Ustundag B, Gecici O, Firidin B. Serum leptin and cholesterol values in suicide attempters. Neuropsychobiology 2002; 45: 124–127.
41. Schilling C, Gilles M, Blum WF, Daseking E, Colla M, Weber-Hamann B et al. Leptin plasma concentrations increase during antidepressant treatment with ami-triptyline and mirtazapine, but not paroxetine and venlafaxine: leptin resistance mediated by antihistaminergic activity? J Clin Psychopharmacol 2013; 33: 99–103.
42. Lu X-Y, Kim CS, Frazer A, Zhang W. Leptin: a potential novel antidepressant. Proc Natl Acad Sci USA 2006; 103: 1593–1598.
43. Loftis JM, Huckans M, Morasco BJ. Neuroimmune mechanisms of cytokine-induced depression: current theories and novel treatment strategies. Neurobiol Dis 2010; 37: 519–533.
44. Van Leeuwen JT. Antidepressants: Types, Efficiency and Possible Side Effects. Nova Science Publishers: New York, NY, USA, 2010.
45. Castren E. Is mood chemistry? Nat Rev Neurosci 2005; 6: 241–246.
46. Duman RS, Heninger GR, Nestler EJ. A molecular and cellular theory of depres-sion. Arch Gen Psychiatry 1997; 54: 597–606.
47. Zhao C, Deng W, Gage FH. Mechanisms and functional implications of adult neurogenesis. Cell 2008; 132: 645–660.
48. Romero-Corral A, Somers VK, Sierra-Johnson J, Thomas RJ, Collazo-Clavell ML, Korinek J et al. Accuracy of body mass index in diagnosing obesity in the adult general population. Int J Obes (Lond) 2008; 32: 959–966.
49. Wolin KY, Petrelli JM. Obesity. Greenwood Press: Santa Barbara, CA, USA, 2009.
50. O'Neill S, O'Driscoll L. Metabolic syndrome: a closer look at the growing epi-demic and its associated pathologies. Obes Rev 2015; 16: 1–12.
51. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009; 120: 1640–1645.
52. Bornstein SR, Schuppenies A, Wong ML, Licinio J. Approaching the shared biology of obesity and depression: the stress axis as the locus of gene-environment interactions. Mol Psychiatry 2006; 11: 892–902.
53. Scott KM, Bruffaerts R, Simon GE, Alonso J, Angermeyer M, de Girolamo G et al. Obesity and mental disorders in the general population: results from the world mental health surveys. Int J Obes (Lond) 2008; 32: 192–200.
54. de Wit L, Luppino F, van Straten A, Penninx B, Zitman F, Cuijpers P. Depression and obesity: a meta-analysis of community-based studies. Psychiatry Res 2010; 178: 230–235.
55. Luppino FS, de Wit LM, Bouvy PF, Stijnen T, Cuijpers P, Penninx BW et al. Overweight, obesity, and depression: a systematic review and meta-analysis of longitudinal studies. Arch Gen Psychiatry 2010; 67: 220–229.
56. Luppino FSDWLM, Bouvy PF, Stijnen T, Cuijpers P, Penninx BJJ, Zitman FG. Overweight, obesity, and depression: a systemic review and meta-analysis of longitudinal studies. Arch Gen Psychiatry 2010; 67: 220–229.
57. Hasler G, Pine DS, Kleinbaum DG, Gamma A, Luckenbaugh D, Ajdacic V et al. Depressive symptoms during childhood and adult obesity: the Zurich Cohort Study. Mol Psychiatry 2005; 10: 842–850.
58. Vogelzangs N, Kritchevsky SB, Beekman AT, Newman AB, Satterfield S, Simonsick EM et al. Depressive symptoms and change in abdominal obesity in older per-sons. Arch Gen Psychiatry 2008; 65: 1386–1393.
59. Qi L, Cho YA. Gene-environment interaction and obesity. Nutr Rev 2008; 66: 684–694.
60. Lin RC, Wang XL, Dalziel B, Caterson ID, Morris BJ. Association of obesity, but not diabetes or hypertension, with glucocorticoid receptor N363S variant. Obes Res 2003; 11: 802–808.
61. Challis BG, Luan J, Keogh J, Wareham NJ, Farooqi IS, O'Rahilly S. Genetic variation in the corticotrophin-releasing factor receptors: identification of single-nucleotide polymorphisms and association studies with obesity in UK Cauca-sians. Int J Obes Relat Metab Disord 2004; 28: 442–446.
62. Lang UE, Hellweg R, Sander T, Gallinat J. The Met allele of the BDNF Val66Met polymorphism is associated with increased BDNF serum concentrations. Mol Psychiatry 2009; 14: 120–122.
63. Pan A, Keum N, Okereke OI, Sun Q, Kivimaki M, Rubin RR et al. Bidirectional association between depression and metabolic syndrome: a systematic review and meta-analysis of epidemiological studies. Diabetes Care 2012; 35: 1171–1180.
64. Vancampfort D, Correll CU, Wampers M, Sienaert P, Mitchell AJ, De Herdt A et al. Metabolic syndrome and metabolic abnormalities in patients with major depressive disorder: a meta-analysis of prevalences and moderating variables. Psychol Med 2014; 44: 2017–2028.
65. Björntorp P. Do stress reactions cause abdominal obesity and comorbidities? Obes Rev 2001; 2: 73–86.
66. Schüle C. Neuroendocrinological mechanisms of actions of antidepressant drugs. J Neuroendocrinol 2007; 19: 213–226.
67. Shelton RC, Falola M, Li L, Zajecka J, Fava M, Papakostas GI. The pro-inflammatory profile of depressed patients is (partly) related to obesity. J Psychiatr Res 2015; 70: 91–97.
68. Wimbiscus M, Kostenko O, Malone D. MAO inhibitors: risks, benefits, and lore. Cleve Clin J Med 2010; 77: 859–882.
69. Fiedorowicz JG, Swartz KL. The role of monoamine oxidase inhibitors in current psychiatric practice. J Psychiatr Pract 2004; 10: 239.
70. Crane GE. Iproniazid (marsilid) phosphate: a therapeutic agent for mental disorders and debilitating diseases. Psychiatr Res Rep 1957; 8: 142–152.
71. Yıldız A, Gönül AS, Tamam L. Mechanism of actions of antidepressants: beyond the receptors. Bull Clin Psychopharmacol 2002; 12: 194–200.
72. Fangmann P, Assion H-J, Juckel G, González CÁ, López-Muñoz F. Half a century of antidepressant drugs: on the clinical introduction of monoamine oxidase inhibitors, tricyclics, and tetracyclics. Part II: tricyclics and tetracyclics. J Clin Psychopharmacol 2008; 28: 1–4.
73. Roose SP, Laghrissi-Thode F, Kennedy JS, Nelson JC, Bigger JT Jr, Pollock BG et al. Comparison of paroxetine and nortriptyline in depressed patients with ischemic heart disease. JAMA 1998; 279: 287–291.
74. Kantor SJ, Glassman AH, Bigger JT, Perel JM, Giardina EV. The cardiac effects of therapeutic plasma concentrations of imipramine. Am J Psychiatry 1978; 135: 534–538.
75. Glassman AH, Roose SP, Bigger J Jr.. The safety of tricyclic antidepressants in cardiac patients: Risk-benefit reconsidered. JAMA 1993; 269: 2673–2675.
76. Berken GH, Weinstein DO, Stern WC. Weight gain: a side-effect of tricyclic antidepressants. J Affect Disord 1984; 7: 133–138.
77. Wong DT, Bymaster FP, Engleman EA. Prozac (Fluoxetine, Lilly 110140), the first selective serotonin uptake inhibitor and an antidepressant drug: twenty years since its first publication. Life Sci 1995; 57: 411–441.
78. Vaswani M, Linda FK, Ramesh S. Role of selective serotonin reuptake inhibitors in psychiatric disorders: a comprehensive review. Prog Neuro-Psychopharmacol Biol Psychiatry 2003; 27: 85–102.
79. Cascade E KA, Kennedy. SH. Real-world data on SSRI antidepressant side effects. Psychiatry (Edgmont) 2009; 6: 16–18.
80. Sussman N, Ginsberg D. Rethinking side effects of the selective serotonin reuptake inhibitors: sexual dysfunction and weight gain. Psychiatr Ann 1998; 28: 89–97.
81. Ferguson JM. SSRI antidepressant medications: adverse effects and tolerability. Prim Care Companion J Clin Psychiatry 2001; 3: 22.
82. Goldstein BJ, Goodnick PJ. Selective serotonin reuptake inhibitors in the treatment of affective disorders—III. Tolerability, safety and pharmacoeconomics. J Psychopharmacol 1998; 12(4 suppl): 55–S87.
83. Mackay FJ, Dunn NR, Wilton LV, Pearce GL, Freemantle SN, Mann RD. A comparison of fluvoxamine, fluoxetine, sertraline and paroxetine examined by observational cohort studies. Pharmacoepidemiol Drug Safety 1997; 6: 235–246.
84. Nelson JC, Mazure CM, Bowers MB Jr, Jatlow PI. A preliminary, open study of the combination of fluoxetine and desipramine for rapid treatment of major depression. Arch Gen Psychiatry 1991; 48: 303.
85. Seth R, Jennings A, Bindman J, Phillips J, Bergmann K. Combination treatment with noradrenalin and serotonin reuptake inhibitors in resistant depression. Br J Psychiatry 1992; 161: 562–565.
86. Briley M. Specific serotonin and noradrenaline reuptake inhibitors (SNRIs). A review of their pharmacology, clinical efficacy and tolerability. Hum Psycho-pharmacol 1998; 13: 99–111.
87. Van Reedt Dortland AKB, Giltay EJ, Van Veen T, Zitman FG, Penninx BWJH. Metabolic syndrome abnormalities are associated with severity of anxiety and depression and with tricyclic antidepressant use. Acta Psychiatr Scand 2010; 122: 30–39.
88. Kivimäki M, Hamer M, Batty GD, Geddes JR, Tabak AG, Pentti J et al. Antidepressant medication use, weight gain, and risk of type 2 diabetes a population-based study. Diabetes Care 2010; 33: 2611–2616.
89. Patten S, Williams J, Lavorato D, Brown L, McLaren L, Eliasziw M. Major depres-sion, antidepressant medication and the risk of obesity. Psychother Psychosom 2009; 78: 182.
90. Andersen S, Clemow D, Corya S. Long-term weight gain in patients treated with open-label olanzapine in combination with fluoxetine for major depressive disorder. J Clin Psychiatry 2005; 66: 1468.
91. Dannon P II, Lowengrub K, Gonopolsky Y, Musin E, Grunhaus L, Kotler M. A naturalistic long-term comparison study of selective serotonin reuptake inhibi-tors in the treatment of panic disorder. Clin Neuropharmacol 2007; 30: 326–334.
92. Michelson D, Amsterdam JD, Quitkin FM, Reimherr FW, Rosenbaum JF, Zajecka J et al. Changes in weight during a 1-year trial of fluoxetine. Am J Psychiatry 1999; 156: 1170–1176.
93. Sussman N, Ginsberg DL, Bikoff J. Effects of nefazodone on body weight: a pooled analysis of selective serotonin reuptake inhibitor-and imipramine-controlled trials. J Clin Psychiatry 2001; 62: 256.
94. Uher R, Mors O, Hauser J, Rietschel M, Maier W, Kozel D et al. Changes in body weight during pharmacological treatment of depression. Int J Neuro-Psychopharmacol 2011; 14: 367.
95. Serretti A ML. Antidepressants and body weight: a comprehensive review and meta-analysis. J Clin Psychiatry 2010; 71: 1259–1271.
96. Apovian CM, Aronne LJ, Bessesen DH, McDonnell ME, Murad MH, Pagotto U et al. Pharmacological management of obesity: an endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2015; 100: 342–362.
97. Christos T, George P, Charalabos P, Dimitris D, Vasilis M, Constantin K et al. Excessive weight gain after remission of depression in a schizophrenic patient treated with risperidone: case report. BMC Psychiatry 2006; 6: 37.
98. Bouwer C, Harvey B. Phasic craving for carbohydrate observed with citalopram. Int Clin Psychopharmacol 1996; 11: 273.
99. Harvey B BC. Neuropharmacology of paradoxic weight gain with selective ser-otonin reuptake inhibitors. Clin Neuropharmacol 2000; 23: 90–97.
100. Pinar M, Gulsun M, Tasci I, Erdil A, Bolu E, Acikel C et al. Maprotiline induced weight gain in depressive disorder: Changes in circulating ghrelin and adipo-nectin levels and insulin sensitivity. Prog Neuro-Psychopharmacol Biol Psychiatry 2008; 32: 135–139.
101. Ishizuka T, Nomura S, Hosoda H, Kangawa K, Watanabe T, Yamatodani A. A role of the histaminergic system for the control of feeding by orexigenic peptides. Physiol Behav 2006; 89: 295–300.
102. Billes SK, Sinnayah P, Cowley MA. Naltrexone/bupropion for obesity: an inves-tigational combination pharmacotherapy for weight loss. Pharmacol Res 2014; 84: 1–11.
103. Moosa MYH, Panz VR, Jeenah FY, Joffe BI. African women with depression: the effect of imipramine and fluoxetine on body mass index and leptin secretion. J Clin Psychopharmacol 2003; 23: 549–552.
104. Dryden S, Frankish H, Wang Q, Pickavance L, Williams G. The serotonergic agent fluoxetine reduces neuropeptide Y levels and neuropeptide Y secretion in the hypothalamus of lean and obese rats. Neuroscience 1996; 72: 557–566.
105. Bhatia N, Maiti PP, Choudhary A, Tuli A, Masih D, Khan MMU et al. Animal models and stress. Int J Pharm Sci Res 2010; 2: 1147–1155.
106. Willner P. The validity of animal models of depression. Psychopharmacology 1984; 83: 1–16.
107. Belzung C, Lemoine M. Criteria of validity for animal models of psychiatric disorders: focus on anxiety disorders and depression. Biol Mood Anxiety Disord 2011; 1: 9.
108. Steru L, Chermat R, Thierry B, Simon P. The tail suspension test: a new method for screening antidepressants in mice. Psychopharmacology 1985; 85: 367–370.
109. Nestler EJ, Gould E, Manji H. Preclinical models: status of basic research in depression. Biol Psychiatry 2002; 52: 503–528.
110. Tye KM, Prakash R, Kim S-Y, Fenno LE, Grosenick L, Zarabi H et al. Amygdala circuitry mediating reversible and bidirectional control of anxiety. Nature 2011; 471: 358–362.
111. Yan H-C, Cao X, Das M, Zhu X-H, Gao T-M. Behavioral animal models of depression. Neurosci Bull 2010; 26: 327–337.
112. Vorhees CV, Williams MT. Morris water maze: procedures for assessing spatial and related forms of learning and memory. Nat Protoc 2006; 1: 848–858.
113. Willner P, Towell A, Sampson D, Sophokleous S, Muscat R. Reduction of sucrose preference by chronic unpredictable mild stress, and its restoration by a tricyclic antidepressant. Psychopharmacology 1987; 93: 358–364.
114. Tschöp M, Heiman ML. Rodent obesity models: an overview. Exp Clin Endocrinol Diabetes 2001; 109: 307–319.
115. Chehab FF, Qiu J, Ogus S. The use of animal models to dissect the biology of leptin. Recent Prog Hormone Res 2004; 59: 245–266.
116. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homologue. Nature 1994; 372: 425–432.
117. Frederich RC, Hamann A, Anderson S, Löllmann B, Lowell BB, Flier JS. Leptin levels reflect body lipid content in mice: evidence for diet-induced resistance to leptin action. Nat Med 1995; 1: 1311–1314.
118. Stephens TW, Basinski M, Bristow PK, Bue-Valleskey JM, Burgett SG, Craft L et al. The role of neuropeptide Y in the antiobesity action of the obese gene product. Nature 1995; 377: 530–532.
119. Hariri N, Thibault L. High-fat diet-induced obesity in animal models. Nutr Res Rev 2010; 23: 270.
120. Buettner R, Schölmerich J, Bollheimer LC. High-fat diets: Modeling the metabolic disorders of human obesity in rodents. Obesity 2007; 15: 798–808.
121. Madsen AN, Hansen G, Paulsen SJ, Lykkegaard K, Tang-Christensen M, Hansen HS et al. Long-term characterization of the diet-induced obese and diet-resistant rat model: a polygenetic rat model mimicking the human obesity syndrome. J Endocrinol 2010; 206: 287–296.
122. Pagliassotti MJ, Knobel SM, Shahrokhi KA, Manzo AM, Hill JO. Time course of adaptation to a high-fat diet in obesity-resistant and obesity-prone rats. Am J Physiol 1994; 267: R659–R664.
123. Huang BW, Chiang MT, Yao HT, Chiang W. The effect of high-fat and high-fructose diets on glucose tolerance and plasma lipid and leptin levels in rats. Diabetes Obes Metab 2004; 6: 120–126.
124. Dourmashkin JT, Chang GQ, Gayles EC, Hill JO, Fried SK, Julien C et al. Different forms of obesity as a function of diet composition. Int J Obes Relat Metab Disord 2005; 29: 1368–1378.
125. Dourmashkin JT, Chang GQ, Hill JO, Gayles EC, Fried SK, Leibowitz SF. Model for predicting and phenotyping at normal weight the long-term propensity for obesity in Sprague–Dawley rats. Physiol Behav 2006; 87: 666–678.
126. Huang XF, Xin X, McLennan P, Storlien L. Role of fat amount and type in ame-liorating diet-induced obesity: insights at the level of hypothalamic arcuate nucleus leptin receptor, neuropeptide Y and pro-opiomelanocortin mRNA expression. Diabetes Obes Metab 2004; 6: 35–44.
127. Manting L, Haihong Z, Jing L, Shaodong C, Yihua L. The model of rat lipid metabolism disorder induced by chronic stress accompanying high-fat-diet. Lipids Health Dis 2011; 28: 153.
128. Chuang J-C, Cui H, Mason BL, Mahgoub M, Bookout AL, Yu HG et al. Chronic social defeat stress disrupts regulation of lipid synthesis. J Lipid Res 2010; 51: 1344–1353.
129. Abildgaard A, Solskov L, Volke V, Harvey BH, Lund S, Wegener G. A high-fat diet exacerbates depressive-like behavior in the Flinders Sensitive Line (FSL) rat, a genetic model of depression. Psychoneuroendocrinology 2011; 36: 623–633.
130. Mastronardi C, Paz-Filho GJ, Valdez E, Maestre-Mesa J, Licinio J, Wong ML. Long-term body weight outcomes of antidepressant-environment interactions. Mol Psychiatry 2011; 16: 265–272.
131. Wieczorek I, Schulz C, Jarry H, Lehnert H. The effects of the selective serotonin reuptake-inhibitor fluvoxamine on body weight in Zucker rats are mediated by corticotropin-releasing hormone. Int J Obes 2001; 25: 1566–1569.
132. Nonogaki K, Nozue K, Kuboki T, Oka Y. Milnacipran, a serotonin and nor-epinephrine reuptake inhibitor, induces appetite-suppressing effects without inducing hypothalamic stress responses in mice. Am J Physiol Regul Integr Comp Physiol 2007; 292: R1775–R1781.
133. Sullivan SD, Howard LC, Clayton AH, Moenter SM. Serotonergic activation rescues reproductive function in fasted mice: Does serotonin mediate the metabolic effects of leptin on reproduction? Biol Reprod 2002; 66: 1702–1706.
134. Portella AK, Silveira PP, Diehl LA, Crema LM, Clemente Z, Peres W et al. Early life handling decreases serotonin turnover in the nucleus accumbens and affects feeding behavior of adult rats. Dev Psychobiol 2010; 52: 190–196.
135. Gamaro GD, Prediger ME, Lopes J, Bassani MG, Dalmaz C. Fluoxetine alters feeding behavior and leptin levels in chronically-stressed rats. Pharmacol Biochem Behav 2008; 90: 312–317.